This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.
Ratos's subsidiary Biolin Scientific has signed an agreement to sell all the shares in its subsidiary Osstell, which manufactures instruments for dental diagnostics, to venture capital company Fouriertransform. The selling price amounts to approximately SEK 33m (enterprise value). The sale is in line with efforts to focus Biolin Scientific's operations on the other business areas, where the growth strategy is unchanged. The sale will not have any significant impact on earnings.
Biolin Scientific develops, manufactures and markets analytical instruments for research, development, quality control and clinical diagnostics. The company's largest market niche is nanotechnology, primarily materials science, cell analysis and biophysics. Customers are found worldwide and mainly comprise researchers in universities, research institutes and the industrial sector. In 2013 Biolin Scientific's sales totalled SEK 233m and EBITA amounted to SEK 23m. The group has approximately 150 employees.
Osstell develops and sells instruments that measure the stability of dental implants and customers are dentists and oral surgeons worldwide. The company has 15 employees and sales in 2013 amounted to SEK 36m.
For further information, please contact:
Henrik Joelsson, Investment Director Ratos, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications Ratos, +8 700 17 20